Agendia last week launched ColoPrint, a microarray-based test based on an 18-gene expression signature that can be used to predict the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.

According to the Dutch firm, ColoPrint provides a "definitive relapse risk assessment" for 100 percent of all stage II patients and "eliminates the gray area of indeterminate results" found in patients using clinical and pathologic factors such as T4-stage and microsatellite instability status.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.